Topic: autoimmune disease
Argenx has data for a subcutaneous formulation of its autoimmune disease drug efgartigimod that could make it a more patient-friendly prospect.
The financing will set Calliditas up to start enrolling autoimmune kidney disease patients in a pivotal trial later this year.
Armed with $65 million in series A funding, Celsius will sequence defined patient samples to identify the individual cells responsible for disease.
Itaconate, a compound produced by inflammatory cells, relieved psoriasis-like symptoms in mice.
Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.
Dracen will advance drugs that stifle a tumor's energy source and boost the immune response to cancer.
The drug discovery-stage company wants to tune the metabolism of immune cells to change their behavior.
The funding will carry Cyteir's RAD51 inhibitors into the clinic for cancer.
AstraZeneca has carved off six inflammation and autoimmune assets to create a new biotech, Viela Bio.
Aldeyra Therapeutics and Janssen inked a pact to develop new drugs for inflammatory diseases.